BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October

Day

• 1
• 3
• 4
• 5
• 6
• 7
• 8
• 9
• 11
• 12
• 13
• 14
• 15
• 18
• 19
• 20
• 21
• 22
• 24
• 25
• 26
• 27
• 28
• 29

• 

  MASH

  Novo Wins MASH Approval for Wegovy

  The label expansion could help Novo Nordisk “help shift the momentum” for Wegovy, after a difficult start to 2025, according to analysts at BMO Capital Markets.

  August 18, 2025

   · 

  2 min read

   · 

  Tristan Manalac
• 

  Sickle cell disease

  Pfizer’s $5.4B GBT Bet Disappoints Again as Sickle Cell Therapy Fails in Phase III

  Inclacumab, which Pfizer obtained in its 2022 acquisition of Global Blood Therapeutics, failed to significantly lower pain episodes in patients with sickle cell disease over the 48-week treatment period.

  August 18, 2025

   · 

  2 min read

   · 

  Tristan Manalac
• 

  Funding

  Gene Therapy Specialist Kriya Raises $313M

  Kriya is advancing a host of gene therapies for a wide variety of chronic diseases, including geographic atrophy, trigeminal neuralgia and type 1 diabetes.

  August 18, 2025

   · 

  2 min read

   · 

  Tristan Manalac
• 

  GLP-1

  Novo Teams Up With GoodRx for Lower-Price GLP-1s, Giving DTC Another Shot

  Patients who are prescribed Wegovy or Ozempic can now use GoodRx to access the medications at just $499 a month if they skip insurance. This is not the first time Novo has partnered with a pharmacy to offer the blockbuster drugs.

  August 18, 2025

   · 

  1 min read

   · 

  Annalee Armstrong
• 

  Pain

  Tonix Wins Approval For First New Fibromyalgia Drug in Over 15 Years

  In Phase III studies, Tonmya showed significantly superior analgesic effects in patients with fibromyalgia versus placebo. The sublingual pill also led to better clinical outcomes.

  August 18, 2025

   · 

  1 min read

   · 

  Tristan Manalac
• 

  Neuroscience

  Merck KGaA Drops up to $2B in Skyhawk Collab for RNA-Targeting Tech

  Waltham, Massachusetts–based Skyhawk Therapeutics has been collecting collaborations with larger companies in spades since launching in 2018.

  August 18, 2025

   · 

  1 min read

   · 

  Dan Samorodnitsky
• 

  FDA

  Leaked MAHA Strategy Emphasizes Vaccine Overhaul, Streamlined Access to Novel Therapies

  A draft copy of the Make America Healthy Again Commission’s latest report, obtained by Politico, focuses on vaccine-related injuries and expediting access to investigational medicines for children—even though the FDA has recently rejected several of them.

  August 18, 2025

   · 

  3 min read

   · 

  Heather McKenzie
• Press Releases

  Ascletis Announces the Combination of ASC47 and ASC31, its Dual GLP-1R/GIPR Peptide Agonist, Demonstrated Significantly Greater Weight Loss Compared to the Combination of ASC47 and Tirzepatide in an Animal Model of Obesity

  August 18, 2025

   · 

  3 min read
• Press Releases

  Ascentage Pharma Announces Global Registrational Phase III Study of Lisaftoclax for First-line Treatment of Patients with Higher-Risk Myelodysplastic Syndrome Cleared by US FDA and EMA

  August 18, 2025

   · 

  11 min read
• Press Releases

  Wegovy® approved by FDA for the treatment of adults with noncirrhotic MASH with moderate to advanced liver fibrosis

  August 18, 2025

   · 

  15 min read